Sedivention

Executive Summary

Sedivention is a German medical device company developing a novel, minimally invasive outpatient therapy for obesity. Its proprietary technology involves a one-time cryo-ablation procedure targeting the gastric trunks of the vagus nerve, aiming to permanently reduce hunger sensation. The company has developed a prototype device and demonstrated proof of concept for safety and efficacy. Obesity is a global epidemic with limited effective long-term treatments, and Sedivention's approach offers a potential one-time solution that could dramatically improve patient outcomes and reduce healthcare costs. The company is privately held and based in Munich, Germany, operating at the intersection of medical devices and drug delivery. Currently at the preclinical stage, Sedivention's next critical milestones include initiating first-in-human clinical trials to validate safety and efficacy in patients. Success would position the company as a frontrunner in interventional obesity therapies. However, the long-term durability of the hunger-reducing effect and potential regulatory hurdles remain key risks. If successful, Sedivention could capture a significant share of the obesity treatment market, which is projected to exceed $50 billion by 2030. The company's innovative approach and clear unmet need make it a compelling opportunity for investors seeking early-stage exposure to the medical device sector.

Upcoming Catalysts (preview)

• Q1 2027First-in-Human Clinical Trial Initiation60% success
• Q4 2027CE Mark Submission for Prototype Device50% success
• Q2 2026Strategic Partnership or Series A/B Funding70% success